-
Post date
May 12, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelic companies, clinical psychedelics, clinical trials psilocybin 2021, cmps.q, COMPASS, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, filament health ipo, Filament Health Natural Psychedelic, filament health neo, Filament Health Trials, filament stock, medical psychedelics, Mind Medicine Inc., MindMEd, mmed.ne, Mushrooms, Natural psilocybin extraction, naturally extracted psilocybin, pharmaceutical grade psilocybin, Psilo Scientific, psilocybin, psilocybin based therapies, psilocybin clinical trials, psilocybin market, psilocybin mushrooms, psilocybin studies, psilocybin studies 2022, Psychedelics, Today's Idea
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
-
Post date
February 10, 2022
-
Posted by
Kieran Robertson
-
Posted in
2021 psychedelics stocks, 2022 canadian psychedelics stocks, 2022 psychedelics stocks, alcohol use disorder, AUD, best psychedelics companies, best psychedelics stocks, best psychedelics stocks 2021, canadian psychedelics stocks, canadian psychedelics stocks 2021, canadian psychedelics stocks 2022, clinical trial, clinical trials cost psychedelics, clinical trials psychedelics, clinical trials psychedelics stocks, companies doing psychedelics research, EntheoTech, EntheoTech Bioscience Inc., FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, Filament Health Trials, financial results, Health Canada approval, how to invest in psychedelics, invest in psychedelics, Major depressive disorder, MDD, medical psychedelics, Mushrooms, NEO, Psychedelics, psychedelics market, Psychedelics research, Q3, Q3 2021, SAP, Special Access Program, Today's Idea
-
Post date
January 25, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelic companies, best psychedelic stocks, best psychedelic treatment, clinical trials psychedelics, companies doing psychedelics research, GAD, Generalized Anxiety Disorder, investing in psychedelics, LSD, LSD research, Major depressive disorder, MDD, medical psychedelics, Mind Medicine, Mind Medicine Inc., MindMEd, MNMD.Q, psychedelic assisted therapy, psychedelic market, Psychedelics, psychedelics stocks, therapy for major depression disorder
